News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
vinanet.vn Earnings
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Clene (Nasdaq: CLNN) announced its management will deliver a virtual corporate update at the Emerging Growth Conference on August 19, 2026, at 3:10 p.m. ET. The presentation will be webcast and a replay will be available afterward. Clene is a biopharmaceutical company developing CNM-Au8, โฆ
H.C. Wainwright has reiterated a Buy rating and a $31 price target for Clene Inc. (NASDAQ:CLNN) after the company received final formal Type C meeting minutes from the FDA, confirming that data could support an accelerated approval pathway for ALS. Clene plans to submit โฆ
Clene (NASDAQ: CLNN) reported its second-quarter earnings, missing analyst EPS estimates by $0.75 with an EPS of $-1.0800, but exceeding revenue expectations with $90K against a consensus of $63.25K. The company's stock has seen a -39.0300% drop in the last three months but is โฆ
This article reports on the filing of a Form 8K by Clene Inc. on August 14th. The brief news item includes the company's stock symbol CLNN and its performance, showing a -1.19% change. It also features various financial market data and related news.
Clene Inc. director David J. Matlin was granted 6,230 stock options on August 13, 2026, under the company's Amended 2020 Stock Plan. These options have an exercise price of $4.19 per share, vest immediately, and are exercisable into 6,230 shares of common stock until โฆ
Clene Inc. (CLNN) reported that its director, Alison Mosca, was granted 4,872 stock options on August 13, 2026. These options were issued under the company's Amended 2020 Stock Plan, have an exercise price of $4.19 per share, and vest immediately. The options are set โฆ
Clene (NASDAQ:CLNN) reported a significant miss on its quarterly earnings, posting a loss of $1.08 per share against an estimated loss of $0.37. Despite exceeding revenue expectations, the company's shares fell by 1.2% to $4.14. Analysts maintain a "Moderate Buy" consensus with a high โฆ
Clene Inc. (CLNNW) reported a net loss of $13.4 million for Q2 2026, widening from the previous year, as the clinical-stage pharmaceutical company continues to invest heavily in developing its novel clean-surfaced nanotechnology therapeutics. The loss per share was $1.08, an increase from $0.78 โฆ
Several Vivo Opportunity entities, including Vivo Opportunity Fund Holdings, L.P. and Vivo Opportunity Cayman Fund, L.P., have disclosed a 9.99% beneficial ownership stake in Clene Inc. (CLNN) through warrants. These warrants, comprising Series A, Series B, and Tranche B, are subject to blocking provisions โฆ
Clene Inc. director Arjun JJ Desai was granted 3,674 stock options on August 13, 2026, with an exercise price of $4.19 per share. These options, granted under the Clene Inc. Amended 2020 Stock Plan, vest immediately and expire on August 12, 2036. This transaction โฆ
Clene reported a significant widening of its Q2 FY26 net loss to $13.42 million, an 81% increase from the previous year, primarily due to a rise in total other expenses. Despite this, revenue saw an increase to $90,000, driven by product revenue, while operating โฆ
Clene Inc. (CLNN) reported a Q2 loss of $0.6 per share, which was wider than the Zacks Consensus Estimate of a $0.37 loss, though an improvement from the $0.78 loss per share a year ago. The company exceeded revenue expectations, posting $0.09 million against โฆ
Clene Inc. reported a widened Q2 2026 net loss of $13.4 million, or $1.08 per share, compared to $7.4 million, or $0.78 per share, in Q2 2025. Despite the increased loss, the company is preparing to submit a New Drug Application (NDA) for its โฆ
Clene reported Q2 2026 financial results and provided updates on its ALS program, CNM-Au8. The company plans to submit a New Drug Application for CNM-Au8 in early Q4 2026 under the FDA's accelerated approval pathway, supported by new biomarker analyses showing improved survival and โฆ
Clene is preparing to submit a new drug application (NDA) in early Q4 for CNM-Au8 as a potential treatment for ALS, following discussions with the FDA. The company's approach centers on neurofilament light (NfL) as a biomarker, having observed a 10% reduction in NfL โฆ
Chidozie Ugwumba, an investor in Clene Inc. (CLNN), has filed an amended Schedule 13G reporting 0% beneficial ownership of the company's common stock. This change occurred because management of the investment portfolio for SymBiosis II, LLC, through which Ugwumba previously held shares, was transferred โฆ
Clene Inc. (NASDAQ:CLNN) has received a "Moderate Buy" consensus rating from analysts, with an average 12-month price target of $33.25. Despite this, the company's shares opened at $5.16, down 2.3%, and remain significantly below their 52-week high. Recent financial results for Clene Inc. fell โฆ
Empery Asset Management, LP initiated a new position in Clene Inc (CLNN), purchasing over 916,000 shares, despite the stock being deemed "Significantly Overvalued" by GuruFocus and experiencing a 16.17% decline since the purchase date. Clene Inc is a clinical-stage pharmaceutical company specializing in nanotechnology โฆ
Clene Inc. announced that new analyses of biomarker data from its CNM-Au8ยฎ trials will be included in its New Drug Application (NDA) for accelerated approval in ALS. These analyses show that patients treated with CNM-Au8 whose neurofilament light chain (NfL) levels declined or stabilized โฆ
Clene Inc. announced positive results from analyses of its Phase 2 ALS trials, showing that patients treated with CNM-Au8 who had declining or stabilized neurofilament light chain (NfL) biomarker levels experienced a significant survival benefit. Participants in the HEALEY ALS Platform Trial showed a โฆ
Clene Inc. (CLNN) is scheduled to announce its Q2'26 earnings on August 17th. The company anticipates a revenue of 61.00 thousand USD and an EPS of (0.37) USD for the quarter. Investors can find more detailed financial information on the CLNN Financials page.
This article from Investing.com announces the filing of a Form 8K by Clene Inc. for August 10th. The brief piece is a direct report of the regulatory filing and includes no further details or analysis beyond this announcement. It serves as a notification to โฆ
Clene Inc. (CLNN) announced new post hoc biomarker analyses for its CNM-Au8 drug in ALS, demonstrating that patients with declining or stabilized neurofilament light chain (NfL) levels experienced significantly longer survival and better functional outcomes. These findings will support a planned New Drug Application โฆ
Clene Inc. insider Chidozie Ugwumba has reported a disposal of beneficial ownership of warrants for 799,358 common shares, held indirectly through SymBiosis II LLC, due to a restructuring. Management of the fund's portfolio transferred to an unaffiliated third party, meaning Ugwumba no longer has โฆ
Empery Asset Management, LP and Ryan M. Lane have disclosed a 7.17% beneficial ownership stake in Clene Inc. (CLNN) through a Schedule 13G SEC filing. This stake represents 916,532 shares of common stock, based on 12,778,307 shares outstanding as of May 11, 2026. The โฆ
This article provides a comprehensive stock analysis of Clene Inc. (CLNN) based on TradingKey's Stock Score. It highlights the company's relatively stable fundamentals, high growth potential, and fair valuation within the Biotechnology & Medical Research industry. Despite recent weak market performance, CLNN shows strong โฆ
Search by ticker symbol or company name and select a result to open its chart.
Start typing to find a stock or ETF.
Choose one or more countries for market search, or include every covered market.
Currently searching United States